Trial Profile
A phase II open-label, multi-centre, randomised, prospective, parallel-group study comparing Topotecan/Carboplatin administered 5 days versus 3 days versus Topotecan monotherapy daily x 5 as second line treatment for patients with relapsed extensive disease small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2011
Price :
$35
*
At a glance
- Drugs Topotecan (Primary) ; Carboplatin
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Top Challenge
- 22 Jul 2011 New trial record